Juluca Shortage: What Providers and Prescribers Need to Know in 2026

As a prescriber, you may be hearing from patients who are having difficulty filling their Juluca (dolutegravir/rilpivirine) prescriptions — despite the fact that Juluca is not listed on the FDA Drug Shortage Database. This is a common and understandable point of confusion, and it reflects the structural access challenges that specialty HIV medications face in the current U.S. healthcare landscape.

This guide is intended to help infectious disease specialists, HIV physicians, and other prescribers of Juluca understand the current access environment, anticipate patient pain points, and deploy the most effective strategies to ensure continuity of care.

Clinical Profile: Who Is Prescribed Juluca?

Juluca is FDA-approved as a complete regimen for the treatment of HIV-1 infection in virologically suppressed adults (HIV-1 RNA <50 copies/mL) who have been on a stable antiretroviral regimen for at least 6 months, have no prior treatment failure, and have no known resistance-associated substitutions to either dolutegravir (an INSTI) or rilpivirine (an NNRTI).

The drug's appeal is its two-drug design — eliminating the NRTI backbone reduces nucleoside analog exposure, which may benefit patients with concerns about long-term renal toxicity, bone density loss, or cardiovascular risk factors associated with tenofovir-containing regimens. This makes Juluca a particularly valuable option for a well-defined subset of patients.

Why Juluca Access Is Challenging: The Specialty Drug Reality

Juluca is classified as a specialty medication, which creates several layers of access complexity that you should anticipate:

Specialty pharmacy routing required. Most retail pharmacies do not stock Juluca. Prescriptions must be routed to specialty pharmacies such as CVS Specialty, Walgreens Specialty, Accredo (Express Scripts), Optum Specialty, or similar networks.

Prior authorization is nearly universal. Most commercial insurers, Medicare Part D plans, and Medicaid managed care plans require prior authorization for Juluca. PA criteria typically require documented viral suppression and no prior virologic failure.

Step therapy may apply. Some plans require documented failure or intolerance of a formulary-preferred regimen before approving Juluca. Understanding your patient's plan formulary can help you anticipate and navigate step therapy requirements proactively.

High tier placement on most formularies. Medicare Part D plans typically place Juluca on Tier 5 (specialty tier), which carries the highest patient cost-sharing. Commercial plans vary, but specialty tier placement is common.

Key Drug Interactions and Contraindications to Review at Prescribing

Before prescribing Juluca, confirm the following contraindications and interaction points are not present in your patient's profile:

Dofetilide: Absolute contraindication — dolutegravir inhibits OCT2/MATE1 transporters, significantly increasing dofetilide plasma concentrations and risk of fatal arrhythmia.

Proton pump inhibitors (PPIs): Contraindicated — PPIs significantly reduce rilpivirine absorption due to increased gastric pH.

Strong CYP3A inducers (rifampin, rifapentine, carbamazepine, phenytoin, phenobarbital, dexamethasone systemic): Contraindicated or not recommended — reduce rilpivirine concentrations substantially.

St. John's wort: Contraindicated — induces CYP3A, reducing both component levels.

Metformin: Dolutegravir increases metformin exposure via OCT2/MATE1 inhibition — dose adjustment of metformin may be needed.

QT-prolonging drugs: Use caution — rilpivirine prolongs the QTc at supratherapeutic doses; consider ECG monitoring if coadministering QT-prolonging agents.

Patient Monitoring Requirements

Patients on Juluca should be monitored with routine HIV care including viral load every 3-6 months, CD4 count annually or as indicated, hepatic function (especially with hepatitis B or C co-infection), and renal function. Notably, because Juluca does not contain tenofovir, it may be preferable for patients with impaired renal function or risk for nephrotoxicity.

Screen for depression and mood changes at each visit — both dolutegravir and rilpivirine have been associated with psychiatric adverse effects, and early identification can prevent unnecessary discontinuation.

Supporting Patient Access: Practical Steps for Your Practice

You can significantly improve your patients' ability to access Juluca by taking these steps at the time of prescribing and at each follow-up:

Route the prescription directly to a specialty pharmacy your practice works with — don't leave patients to navigate this themselves.

Submit prior authorization documentation promptly and completely. Include evidence of viral suppression, length of current ART therapy, and absence of resistance if available.

Track PA renewal dates in your EHR and initiate the renewal 30 days before expiration.

Enroll patients in ViiV Connect (1-844-588-3288) at the time of prescribing — the program provides manufacturer support for access and savings.

For uninsured or underinsured patients, submit a patient assistance program application to ViiV Healthcare — eligible patients can receive Juluca at no cost.

medfinder for Providers: A Tool to Help Patients Find Juluca Near Them

When patients are discharged or come in urgently and need to find Juluca at a local pharmacy, medfinder for providers is a service that calls pharmacies on the patient's behalf to check real-time availability. This is especially useful when your specialty pharmacy network doesn't have it immediately available and the patient needs a localized in-person fill. Results are texted directly to the patient.

For a step-by-step guide to helping your patients locate Juluca in your area, see our article on how to help your patients find Juluca in stock.